Long-term study of mycophenolate mofetil treatment in IgA nephropathy

Slides:

Advertisements

Similar presentations

Volume 82, Issue 12, Pages (December 2012)

Advertisements

Sushrut S. Waikar, Venkata S. Sabbisetti, Joseph V. Bonventre

Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation Anil K. Bidani, M.D., Karen A. Griffin,

Volume 92, Issue 1, Pages (July 2017)

C-reactive protein and dialysis access

Rajiv Agarwal, John W. Kusek, Maria K. Pappas Kidney International

Membranous nephropathy: When and how to treat

Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes Robert W. Schrier, Raymond.

Mycophenolate mofetil treatment for primary glomerular diseases

Peter Rossing, Philip Hougaard, Hans-Henrik Parving

C-reactive protein and dialysis access

G protein β3 subunit C825T polymorphism in primary IgA nephropathy

Volume 88, Issue 2, Pages (August 2015)

‘Progressive diabetic nephropathy. How useful is microalbuminuria

Volume 82, Issue 12, Pages (December 2012)

Volume 63, Issue 3, Pages (March 2003)

The Validity of Drug Effects on Proteinuria, Albuminuria, Serum Creatinine, and Estimated GFR as Surrogate End Points for ESKD: A Systematic Review Suetonia.

How to interpret the eGFR in patients with small body surface area

Volume 54, Issue 4, Pages (October 1998)

Volume 74, Issue 3, Pages (August 2008)

Steven J. Rosansky, Richard J. Glassock Kidney International

Volume 82, Issue 3, Pages (August 2012)

Volume 77, Issue 7, Pages (April 2010)

Renal risk scores: Progress and prospects

Volume 79, Issue 9, Pages (May 2011)

Volume 75, Issue 12, Pages (June 2009)

Volume 76, Issue 10, Pages (November 2009)

Volume 76, Issue 6, Pages (September 2009)

Aggressive blood pressure reduction and renin–angiotensin system blockade in chronic kidney disease: time for re-evaluation? Pantelis A. Sarafidis, Luis.

Volume 81, Issue 6, Pages (March 2012)

Volume 81, Issue 5, Pages (March 2012)

Volume 75, Issue 12, Pages (June 2009)

Volume 68, Issue 2, Pages (August 2005)

Volume 57, Issue 1, Pages (January 2000)

Volume 76, Issue 3, Pages (August 2009)

Volume 66, Issue 2, Pages (August 2004)

Volume 82, Issue 7, Pages (October 2012)

Linda F. Fried, Trevor J. Orchard, Bertram L. Kasiske

Proteinuria and hypertensive nephrosclerosis in African Americans

Volume 84, Issue 5, Pages (November 2013)

Volume 56, Issue 5, Pages (November 1999)

Volume 60, Issue 1, Pages (July 2001)

Volume 80, Issue 3, Pages (August 2011)

Volume 62, Pages S47-S52 (December 2002)

Douglas G Matsell, Colin T White Kidney International

Lamivudine in hepatitis B-associated membranous nephropathy

Volume 58, Issue 5, Pages (November 2000)

Volume 77, Issue 11, Pages (June 2010)

Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors Barry M. Brenner, Joann Zagrobelny

Volume 74, Issue 9, Pages (November 2008)

The course of the remnant kidney model in mice

Volume 64, Issue 2, Pages (August 2003)

Volume 65, Issue 5, Pages (May 2004)

Volume 80, Issue 10, Pages (November 2011)

Volume 60, Issue 3, Pages (September 2001)

Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension Julian Segura, Carlos Campo, Luis M. Ruilope Kidney.

Michael R. Lattanzio, Matthew R. Weir Kidney International

Volume 75, Issue 1, Pages (January 2009)

Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular.

Importance of blood pressure control in hemodialysis patient survival

Volume 65, Issue 1, Pages (January 2004)

Volume 87, Issue 3, Pages (March 2015)

Giuseppe Remuzzi, Carlos Chiurchiu, Piero Ruggenenti

Volume 58, Issue 2, Pages (August 2000)

Longitudinal relationships between diet-dependent renal acid load and blood pressure development in healthy children Danika Krupp, Lijie Shi, Thomas.

Volume 69, Issue 11, Pages (June 2006)

Volume 77, Issue 12, Pages (June 2010)

Volume 73, Issue 11, Pages (June 2008)

Volume 60, Issue 2, Pages (August 2001)

Figure 1. (A) Composite renal outcome, (B) worsening kidney function, and (C) incident albuminuria by fasting glucose ... Figure 1. (A) Composite renal.

Presentation transcript:

Long-term study of mycophenolate mofetil treatment in IgA nephropathy Sydney C.W. Tang, Anthony W.C. Tang, Sunny S.H. Wong, Joseph C.K. Leung, Yiu Wing Ho, Kar Neng Lai Kidney International Volume 77, Issue 6, Pages 543-549 (March 2010) DOI: 10.1038/ki.2009.499 Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 1 Kaplan–Meier analysis of overall renal survival of 40 IgAN subjects over the 6-year follow-up period. Ctl, control; MMF, mycophenolate mofetil. Kidney International 2010 77, 543-549DOI: (10.1038/ki.2009.499) Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 2 Kaplan–Meier analysis of the likelihood of not reaching the primary composite end point of doubling of serum creatinine, dialysis, or death of 40 IgAN subjects over the 6-year follow-up period. Kidney International 2010 77, 543-549DOI: (10.1038/ki.2009.499) Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 3 Proteinuria change from baseline to study end. (a) Changes in urinary protein excretion during follow-up. The geometric mean values, with 95% confidence intervals, are shown. *P=0.019, †P=0.023, ‡P=0.007 versus the control group at the corresponding time point. (b) Changes in urinary albumin-to-creatinine ratio during follow-up. The geometric mean values, with 95% confidence intervals, are shown. *P=0.019, †P=0.006, ‡P=0.027 versus the control group at the corresponding time point. Kidney International 2010 77, 543-549DOI: (10.1038/ki.2009.499) Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 4 Annual change in estimated GFR. (a) The rates of change in eGFR over the study period were calculated for each patient by linear regression analysis. The median change in eGFR, indicted by the horizontal line, was -1.125 ml/min per 1.73 m2 per year in the MMF group and -3.812 ml/min per 1.73 m2 per year in the control group (P=0.021). (b) The annualized rates of change in eGFR over the study period according to the type of angiotensin blockade given: ACEi (open circle), ARB (half-filled circle), and combination (solid circle). Kidney International 2010 77, 543-549DOI: (10.1038/ki.2009.499) Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 5 Changes in systolic and diastolic blood pressure. Between-group differences for both systolic and diastolic blood pressures were not statistically significant at each time point. Kidney International 2010 77, 543-549DOI: (10.1038/ki.2009.499) Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 6 Pearson's correlation between reduction in urinary protein excretion at 6 months and the slope of eGFR over time. Kidney International 2010 77, 543-549DOI: (10.1038/ki.2009.499) Copyright © 2010 International Society of Nephrology Terms and Conditions